Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

The partners will assess potential biomarkers, beyond KRAS, of response to cancer drug cetuximab (Erbitux).

Synlab has started offering Epi proColon, Epigenomics' PCR-based blood test for early detection of colorectal cancer, through 55 German sites in its network. In addition, Epigenomics recently raised €33.1 million ($44.2 million) through a combined private and public share offering.

PCR Insider spoke with Mohammad Ilyas of the Queen's Medical Centre at Nottingham University about using quick-multiplex-consensus PCR followed by high-resolution melting to detect mutations in formalin-fixed, paraffin-embedded tissue.

When Vectibix received approval from the US Food and Drug Administration in 2006, "Amgen already knew the response rate was low," according to an Amgen official. The company began collecting patient tissue samples from mid-2005 to early 2007, knowing it would "need those samples for a biomarker analysis."

"DxS is seeking to avoid its exclusive obligation with Roche because it no longer finds it advantageous to benefit from the Roche distribution network," but a termination of the agreement would cause "irreparable" harm, Roche stated in a recently filed complaint.

The CDC's Muin Khoury is disappointed in the paucity of genomics-related prevention and education objectives that have been proposed as part of the US federal government's Healthy People 2020 project.

"Our data reinforce the importance of the KRAS mutation as a predictive biomarker for responsiveness to Vectibix therapy," said Roger Perlmutter, Amgen's executive vice president of research and development.

If the researchers are successful, GMU's Emanuel Petricoin believes it could lead to the development of the first ever protein activation companion assay.

New Releases: Jan 13, 2010

Premium

Abbott/Quest/Epigenomics' Septin 9 Colorectal Cancer Test

Genomic Health will also hire additional sales people in connection with the launch, President and CEO Kim Popovits said yesterday at the JP Morgan Healthcare Conference.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.